Home World News FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory... World News FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 275 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR From smart knives to virtual reality tumours: five innovations in understanding... August 29, 2022 Severe mental illness linked to low attendance at cancer screening May 4, 2023 Teacher Battling Cancer Gifted Free School Supplies August 25, 2021 NHS England change of chief executive – what does it mean... August 19, 2021 Load more HOT NEWS FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show [ESMO2020... Interactive App Improves Colorectal Cancer Screening Rates No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in...